Mimedx (MDXG) EBIAT (2016 - 2025)
Mimedx (MDXG) has disclosed EBIAT for 15 consecutive years, with $15.2 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 93.29% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.6 million through Dec 2025, up 13.99% year-over-year, with the annual reading at $48.6 million for FY2025, 14.52% up from the prior year.
- EBIAT hit $15.2 million in Q4 2025 for Mimedx, down from $16.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $62.7 million in Q4 2023 to a low of -$10.9 million in Q2 2022.
- Historically, EBIAT has averaged $7.0 million across 5 years, with a median of $7.9 million in 2024.
- Biggest five-year swings in EBIAT: plummeted 510.91% in 2022 and later surged 576.88% in 2024.
- Year by year, EBIAT stood at $2.2 million in 2021, then soared by 343.79% to $9.8 million in 2022, then soared by 537.72% to $62.7 million in 2023, then crashed by 87.46% to $7.9 million in 2024, then skyrocketed by 93.29% to $15.2 million in 2025.
- Business Quant data shows EBIAT for MDXG at $15.2 million in Q4 2025, $16.7 million in Q3 2025, and $9.6 million in Q2 2025.